KR102000485B1 - [(3-히드록시피리딘-2-카보닐)아미노]알칸산, 에스테르 및 아미드의 제조공정 - Google Patents

[(3-히드록시피리딘-2-카보닐)아미노]알칸산, 에스테르 및 아미드의 제조공정 Download PDF

Info

Publication number
KR102000485B1
KR102000485B1 KR1020147000297A KR20147000297A KR102000485B1 KR 102000485 B1 KR102000485 B1 KR 102000485B1 KR 1020147000297 A KR1020147000297 A KR 1020147000297A KR 20147000297 A KR20147000297 A KR 20147000297A KR 102000485 B1 KR102000485 B1 KR 102000485B1
Authority
KR
South Korea
Prior art keywords
ring
substituted
units
delete delete
methylphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147000297A
Other languages
English (en)
Korean (ko)
Other versions
KR20140037192A (ko
Inventor
크리스토퍼 엠. 란씨어
보리스 고린
쟌 오우데네스
크레이그 에드워드 딕슨
앨런 퀴그보 루
제임스 덴스모어 콥
존 마이클 자누스
Original Assignee
아케비아 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아케비아 테라퓨틱스 인코포레이티드 filed Critical 아케비아 테라퓨틱스 인코포레이티드
Publication of KR20140037192A publication Critical patent/KR20140037192A/ko
Application granted granted Critical
Publication of KR102000485B1 publication Critical patent/KR102000485B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/803—Processes of preparation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/824—Palladium

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
KR1020147000297A 2011-06-06 2012-06-05 [(3-히드록시피리딘-2-카보닐)아미노]알칸산, 에스테르 및 아미드의 제조공정 Active KR102000485B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161493536P 2011-06-06 2011-06-06
US61/493,536 2011-06-06
PCT/US2012/040833 WO2012170377A1 (en) 2011-06-06 2012-06-05 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides

Related Child Applications (2)

Application Number Title Priority Date Filing Date
KR1020197007633A Division KR102032864B1 (ko) 2011-06-06 2012-06-05 [(3-히드록시피리딘-2-카보닐)아미노]알칸산, 에스테르 및 아미드의 제조공정
KR1020197007630A Division KR102059366B1 (ko) 2011-06-06 2012-06-05 [(3-히드록시피리딘-2-카보닐)아미노]알칸산, 에스테르 및 아미드의 제조공정

Publications (2)

Publication Number Publication Date
KR20140037192A KR20140037192A (ko) 2014-03-26
KR102000485B1 true KR102000485B1 (ko) 2019-07-16

Family

ID=47262177

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020197007633A Active KR102032864B1 (ko) 2011-06-06 2012-06-05 [(3-히드록시피리딘-2-카보닐)아미노]알칸산, 에스테르 및 아미드의 제조공정
KR1020207029586A Active KR102293016B1 (ko) 2011-06-06 2012-06-05 [(3-히드록시피리딘-2-카보닐)아미노]알칸산, 에스테르 및 아미드의 제조공정
KR1020147000297A Active KR102000485B1 (ko) 2011-06-06 2012-06-05 [(3-히드록시피리딘-2-카보닐)아미노]알칸산, 에스테르 및 아미드의 제조공정
KR1020197007630A Active KR102059366B1 (ko) 2011-06-06 2012-06-05 [(3-히드록시피리딘-2-카보닐)아미노]알칸산, 에스테르 및 아미드의 제조공정
KR1020197037296A Active KR102171315B1 (ko) 2011-06-06 2012-06-05 [(3-히드록시피리딘-2-카보닐)아미노]알칸산, 에스테르 및 아미드의 제조공정

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020197007633A Active KR102032864B1 (ko) 2011-06-06 2012-06-05 [(3-히드록시피리딘-2-카보닐)아미노]알칸산, 에스테르 및 아미드의 제조공정
KR1020207029586A Active KR102293016B1 (ko) 2011-06-06 2012-06-05 [(3-히드록시피리딘-2-카보닐)아미노]알칸산, 에스테르 및 아미드의 제조공정

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020197007630A Active KR102059366B1 (ko) 2011-06-06 2012-06-05 [(3-히드록시피리딘-2-카보닐)아미노]알칸산, 에스테르 및 아미드의 제조공정
KR1020197037296A Active KR102171315B1 (ko) 2011-06-06 2012-06-05 [(3-히드록시피리딘-2-카보닐)아미노]알칸산, 에스테르 및 아미드의 제조공정

Country Status (23)

Country Link
US (6) US9145366B2 (cg-RX-API-DMAC7.html)
EP (5) EP3290404B1 (cg-RX-API-DMAC7.html)
JP (6) JP6290781B2 (cg-RX-API-DMAC7.html)
KR (5) KR102032864B1 (cg-RX-API-DMAC7.html)
CN (1) CN106518759B (cg-RX-API-DMAC7.html)
AU (4) AU2012268426B2 (cg-RX-API-DMAC7.html)
CA (2) CA2838194C (cg-RX-API-DMAC7.html)
CY (4) CY1117177T1 (cg-RX-API-DMAC7.html)
DK (4) DK3290404T3 (cg-RX-API-DMAC7.html)
ES (4) ES2900572T3 (cg-RX-API-DMAC7.html)
HR (4) HRP20211916T1 (cg-RX-API-DMAC7.html)
HU (4) HUE048044T2 (cg-RX-API-DMAC7.html)
IL (1) IL229775A (cg-RX-API-DMAC7.html)
LT (3) LT3683209T (cg-RX-API-DMAC7.html)
MX (2) MX337216B (cg-RX-API-DMAC7.html)
NO (1) NO2686520T3 (cg-RX-API-DMAC7.html)
PL (4) PL3683209T3 (cg-RX-API-DMAC7.html)
PT (4) PT3000808T (cg-RX-API-DMAC7.html)
RS (3) RS59902B1 (cg-RX-API-DMAC7.html)
RU (2) RU2602083C2 (cg-RX-API-DMAC7.html)
SI (4) SI2718265T1 (cg-RX-API-DMAC7.html)
SM (3) SMT202000061T1 (cg-RX-API-DMAC7.html)
WO (1) WO2012170377A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009000286A (es) 2006-06-26 2009-03-20 Procter & Gamble Inhibidores de prolil hidroxilasa y metodos de uso.
NO2686520T3 (cg-RX-API-DMAC7.html) 2011-06-06 2018-03-17
PT3007695T (pt) * 2013-06-13 2024-03-07 Akebia Therapeutics Inc Composições e métodos para tratamento de anemia
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
US10065928B2 (en) 2014-09-02 2018-09-04 Sunshine Lake Pharma Co., Ltd. Quinolinone compound and use thereof
CN107427503A (zh) 2015-01-23 2017-12-01 阿克比治疗有限公司 2‑(5‑(3‑氟苯基)‑3‑羟基吡啶甲酰胺)乙酸的固体形式、其组合物及用途
WO2016153996A1 (en) * 2015-03-20 2016-09-29 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
CN106146395B (zh) * 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
CR20170450A (es) 2015-04-01 2018-04-03 Akebia Therapeutics Inc Composiciones y métodos para el tratamiento de la anemia
CN110088088B (zh) * 2016-12-13 2022-03-29 苏州科睿思制药有限公司 {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法
IL269623B2 (en) * 2017-03-29 2025-05-01 Emerald Health Pharmaceuticals Inc Cannabidiol derivatives as inhibitors of the hif prolyl hydroxylases activity
WO2019028150A1 (en) 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
US11713298B2 (en) * 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
WO2020075199A1 (en) 2018-10-12 2020-04-16 Mylan Laboratories Limited Polymorphic forms of vadadustat
US11970450B2 (en) 2018-11-28 2024-04-30 Sandoz Ag Multi-component crystals of an orally available HIF prolyl hydroxylase inhibitor
WO2020217733A1 (ja) * 2019-04-26 2020-10-29 株式会社カネカ Ｖａｄａｄｕｓｔａｔ中間体の製造方法
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
CN111087343B (zh) * 2019-11-29 2022-02-18 万华化学集团股份有限公司 一种羟基吡啶配体及其制备方法和催化应用
US20230159462A1 (en) * 2019-12-10 2023-05-25 Akebia Therapeutics, Inc. Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative
JP7690165B2 (ja) 2020-01-24 2025-06-10 Ａｐｓジャパン株式会社 光触媒ユニット及び該光触媒ユニットを備えたマスク
WO2022006427A1 (en) 2020-07-02 2022-01-06 Akebia Therapeutics, Inc. Manufacturing process for 3,5-dichloropicolinonitrile for synthesis of vadadustat
GB202011431D0 (en) * 2020-07-23 2020-09-09 Johnson Matthey Plc Polymorphs of vadadustat and methods for preparing the polymorphs
EP4447963A1 (en) 2021-12-17 2024-10-23 Akebia Therapeutics Inc. Selective phd1 inhibitor compounds, compositions, and methods of use
EP4661861A1 (en) 2023-02-06 2025-12-17 Institut National de la Santé et de la Recherche Médicale Use of hif-1a stabilizing agents for the treatment of type i interferonopathies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010113942A1 (ja) * 2009-03-31 2010-10-07 キッセイ薬品工業株式会社 インドリジン誘導体及びその医薬用途

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655679A (en) * 1969-06-25 1972-04-11 Merck & Co Inc Certain aryl pyridine carboxylic acid derivatives
US3703582A (en) * 1970-04-20 1972-11-21 Merck & Co Inc Aryl pyridine carboxylic acids in the treatment of inflammation
US3894920A (en) 1971-12-21 1975-07-15 Sagami Chem Res Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
TW219933B (cg-RX-API-DMAC7.html) 1990-02-26 1994-02-01 Lilly Co Eli
US5405613A (en) 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4219158A1 (de) 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP0650961B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
DE59401923D1 (de) 1993-11-02 1997-04-10 Hoechst Ag Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
TW406076B (en) 1993-12-30 2000-09-21 Hoechst Ag Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
DE4410423A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410480A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5789426A (en) 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
WO1997041103A1 (de) 1996-04-30 1997-11-06 Hoechst Aktiengesellschaft 3-alkoxypyridin-2-carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19650215A1 (de) 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
EP1024134A4 (en) 1997-10-09 2003-05-14 Ono Pharmaceutical Co DERIVATIVES OF AMINOBUTANIC ACID
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
JP4495339B2 (ja) 1998-03-23 2010-07-07 アベンティス・ファーマスーティカルズ・インコーポレイテツド ピペリジニルおよびｎ−アミジノピペリジニル誘導体
US6159379A (en) 1999-05-04 2000-12-12 Baker Hughes Incorporated Organic ammonium salts for the removal of water soluble organics in produced water
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
JP4590157B2 (ja) 2001-03-21 2010-12-01 アイシス イノヴェイション リミテッド アッセイ、方法および手段
SE0101327D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab New crystalline forms
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
ES2686625T3 (es) 2001-12-06 2018-10-18 Fibrogen, Inc. Métodos para el tratamiento o prevención de la anemia
WO2003097040A1 (en) 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
AU2003265674B2 (en) * 2002-08-29 2008-12-11 Merck & Co., Inc. N-biarylmethyl aminocycloalkanecarboxamide derivatives
EP1554394B1 (en) 2002-10-16 2009-12-16 Isis Innovation Limited Screening methods using a structural model of FIH
CA2506799A1 (en) 2002-11-21 2004-06-10 Eli Lilly And Company Mixed lineage kinase modulators
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US20060251638A1 (en) 2003-06-06 2006-11-09 Volkmar Guenzler-Pukall Cytoprotection through the use of hif hydroxylase inhibitors
KR100932169B1 (ko) 2003-06-06 2009-12-16 피브로겐, 인크. 질소-함유 헤테로아릴 화합물 및 내인성 적혈구생성소의증가에서의 그들의 사용
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
JPWO2005108370A1 (ja) 2004-04-16 2008-03-21 味の素株式会社 ベンゼン化合物
ES2332798T3 (es) 2004-05-28 2010-02-12 Fibrogen, Inc. Ensayo de actividad de la prolil hidroxilasa de hif.
EP1771418A2 (en) 2004-05-31 2007-04-11 Tanabe Seiyaku Co., Ltd. Large conductance calcium-activated k channel opener
CA2573185A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
TW200616969A (en) 2004-09-17 2006-06-01 Tanabe Seiyaku Co Imidazole compound
US20080213404A1 (en) 2005-02-04 2008-09-04 Johnson Randall S Hif Modulating Compounds and Methods of Use Thereof
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
CN101849943A (zh) 2005-06-06 2010-10-06 菲布罗根公司 使用HIFα稳定剂的改进的贫血治疗
EP1919463B9 (en) 2005-06-15 2011-02-02 Fibrogen, Inc. Use of hif 1alfa modulators for treatment of cancer
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
US20090176726A1 (en) 2005-10-11 2009-07-09 Fisher David E Methods for treating mitf-related disorders
US7728130B2 (en) 2005-12-09 2010-06-01 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity
GB2453819A (en) 2006-01-09 2009-04-22 Btg Int Ltd Modulators of hypoxia inducible factor-1 and related uses
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
TW200738709A (en) 2006-01-19 2007-10-16 Osi Pharm Inc Fused heterobicyclic kinase inhibitors
JP4801451B2 (ja) 2006-01-19 2011-10-26 株式会社日立ハイテクノロジーズ 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
ITMI20060179A1 (it) 2006-02-02 2007-08-03 Abiogen Pharma Spa Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
US7625927B2 (en) 2006-02-27 2009-12-01 Alcon Research, Ltd. Method of treating glaucoma
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
AR059733A1 (es) 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
US20090176825A1 (en) 2006-05-16 2009-07-09 Fitch Duke M Prolyl hydroxylase inhibitors
AR061570A1 (es) 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto
MX2009000286A (es) * 2006-06-26 2009-03-20 Procter & Gamble Inhibidores de prolil hidroxilasa y metodos de uso.
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
CL2008000066A1 (es) 2007-01-12 2008-08-01 Smithkline Beecham Corp Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
CN101663037A (zh) 2007-04-18 2010-03-03 默克公司 新的1,8-二氮杂萘化合物
ES2446418T3 (es) 2007-04-18 2014-03-07 Amgen, Inc Derivados de indanona que inhiben la prolil hidroxilasa
ES2389063T3 (es) 2007-05-04 2012-10-22 Amgen, Inc Derivados de tienopiridina y tiazolopiridina que inhiben la actividad prolil hidroxilasa
WO2008144266A1 (en) 2007-05-16 2008-11-27 Merck & Co., Inc. Spiroindalones
RU2009146851A (ru) 2007-05-18 2011-06-27 Байер Шеринг Фарма Акциенгезельшафт (DE) Гетероарил-замещенные пиразольные производные, которые могут использоваться для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом
EP2186528B1 (en) 2007-08-06 2014-03-19 Senju Pharmaceutical Co., Ltd. Pharmaceutical containing hif-1 alpha and hif-2 alpha expression inhibitor
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
CN101815718A (zh) 2007-08-10 2010-08-25 克里斯捷诺米有限公司 吡啶衍生物及其用法
WO2009035534A2 (en) 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009043093A1 (en) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009067790A1 (en) 2007-11-26 2009-06-04 Uti Limited Partnership STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
EA201000920A1 (ru) 2007-11-30 2011-02-28 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Ингибиторы пролилгидроксилазы
AU2008331480A1 (en) 2007-11-30 2009-06-11 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
US20100298324A1 (en) 2007-12-19 2010-11-25 Smith Kline Beecham Corporation Prolyl Hydroxylase Inhibitors
WO2009086592A1 (en) 2008-01-04 2009-07-16 Garvan Institute Of Medical Research Method of increasing metabolism
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
JP5380465B2 (ja) * 2008-03-03 2014-01-08 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｔｌｒ活性モジュレーターとしての化合物および組成物
US20090228298A1 (en) * 2008-03-04 2009-09-10 The General Electric Company System and method of morphology feature analysis of physiological data
NZ588633A (en) * 2008-03-20 2012-03-30 Forest Lab Holdings Ltd NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
WO2010010017A1 (en) 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
NZ591394A (en) 2008-09-15 2013-03-28 Kasina Laila Innova Pharmaceuticals Private Ltd Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
AU2009314155B2 (en) 2008-11-14 2015-10-08 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors
PL2496236T4 (pl) 2009-11-06 2015-11-30 Aerpio Therapeutics Inc Inhibitory hydroksylazy prolilowej
CA2837560C (en) * 2011-06-06 2017-02-14 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
NO2686520T3 (cg-RX-API-DMAC7.html) 2011-06-06 2018-03-17
US20130022974A1 (en) 2011-06-17 2013-01-24 The Regents Of The University Of Michigan Dna methylation profiles in cancer
US9206134B2 (en) 2011-07-22 2015-12-08 Beijing Betta Pharmaceuticals Co. Ltd. Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
PT3007695T (pt) 2013-06-13 2024-03-07 Akebia Therapeutics Inc Composições e métodos para tratamento de anemia
RU2016109125A (ru) 2013-08-16 2017-09-22 Огайо Стейт Инновейшн Фаундейшн Композиции и способы модуляции метилирования днк
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
WO2015112831A1 (en) 2014-01-23 2015-07-30 Akebia Therapeutics, Inc. Compositions and methods for treating ocular diseases
CN107427503A (zh) 2015-01-23 2017-12-01 阿克比治疗有限公司 2‑(5‑(3‑氟苯基)‑3‑羟基吡啶甲酰胺)乙酸的固体形式、其组合物及用途
WO2016153996A1 (en) 2015-03-20 2016-09-29 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
CR20170450A (es) 2015-04-01 2018-04-03 Akebia Therapeutics Inc Composiciones y métodos para el tratamiento de la anemia
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010113942A1 (ja) * 2009-03-31 2010-10-07 キッセイ薬品工業株式会社 インドリジン誘導体及びその医薬用途

Also Published As

Publication number Publication date
KR20190141805A (ko) 2019-12-24
RU2013158640A (ru) 2015-07-20
SMT201600013B (it) 2016-02-25
SMT202000061T1 (it) 2020-03-13
JP2021059573A (ja) 2021-04-15
US20190375713A1 (en) 2019-12-12
EP3683209B1 (en) 2021-11-10
JP6510094B2 (ja) 2019-05-08
AU2017202414B2 (en) 2018-07-19
CA2838194A1 (en) 2012-12-13
EP2718265A4 (en) 2014-11-19
US20210122715A1 (en) 2021-04-29
DK3290404T3 (da) 2020-02-17
EP3000808A1 (en) 2016-03-30
DK3683209T3 (da) 2021-12-06
PT3290404T (pt) 2020-02-19
KR102171315B1 (ko) 2020-10-28
HRP20211916T1 (hr) 2022-03-18
HRP20171740T1 (hr) 2018-03-09
LT3000808T (lt) 2018-01-25
CN106518759A (zh) 2017-03-22
PT3683209T (pt) 2021-12-15
SI3000808T1 (en) 2018-02-28
EP3683209A1 (en) 2020-07-22
PL3683209T3 (pl) 2022-02-21
EP2718265B1 (en) 2015-12-16
ES2900572T3 (es) 2022-03-17
MX337216B (es) 2016-02-18
PT2718265E (pt) 2016-02-15
EP3000808B1 (en) 2017-09-27
US9776969B2 (en) 2017-10-03
RS54517B1 (sr) 2016-06-30
ES2647602T3 (es) 2017-12-22
ES2771232T3 (es) 2020-07-06
AU2012268426A1 (en) 2014-01-09
KR102293016B1 (ko) 2021-08-26
IL229775A (en) 2016-06-30
DK3000808T3 (da) 2017-11-27
RU2764667C2 (ru) 2022-01-19
US10246416B2 (en) 2019-04-02
RS56580B1 (sr) 2018-02-28
JP6290781B2 (ja) 2018-03-07
JP2019123741A (ja) 2019-07-25
EP2718265A1 (en) 2014-04-16
KR102032864B1 (ko) 2019-10-16
CA2838194C (en) 2022-01-11
PL3000808T3 (pl) 2018-03-30
RU2016139352A (ru) 2018-12-13
KR20200121911A (ko) 2020-10-26
NO2686520T3 (cg-RX-API-DMAC7.html) 2018-03-17
HUE034975T2 (en) 2018-05-02
SI2718265T1 (sl) 2016-03-31
WO2012170377A1 (en) 2012-12-13
LT3683209T (lt) 2022-01-10
HRP20200197T1 (hr) 2020-05-15
AU2018250355A1 (en) 2018-11-08
PL3290404T3 (pl) 2020-06-01
SI3683209T1 (sl) 2022-03-31
JP2018111697A (ja) 2018-07-19
AU2012268426B2 (en) 2017-02-16
RU2016139352A3 (cg-RX-API-DMAC7.html) 2020-01-27
HK1196616A1 (zh) 2014-12-19
DK2718265T3 (en) 2016-01-25
HUE026096T2 (en) 2016-05-30
CY1124874T1 (el) 2022-11-25
CY1119605T1 (el) 2018-04-04
KR20190032617A (ko) 2019-03-27
US11267785B2 (en) 2022-03-08
US20230002323A1 (en) 2023-01-05
US20170362178A1 (en) 2017-12-21
RU2602083C2 (ru) 2016-11-10
US20150361043A1 (en) 2015-12-17
HRP20151416T1 (hr) 2016-03-25
CY1117177T1 (el) 2017-04-05
JP2023103414A (ja) 2023-07-26
KR102059366B1 (ko) 2019-12-26
AU2018250355B2 (en) 2020-04-09
RS59902B1 (sr) 2020-03-31
US9145366B2 (en) 2015-09-29
CN106518759B (zh) 2019-07-30
AU2017202414A1 (en) 2017-05-04
JP7284309B2 (ja) 2023-05-30
HK1216173A1 (en) 2016-10-21
MX2013014228A (es) 2014-03-26
KR20140037192A (ko) 2014-03-26
JP7685552B2 (ja) 2025-05-29
US10738010B2 (en) 2020-08-11
EP3290404A1 (en) 2018-03-07
SI3290404T1 (sl) 2020-03-31
HK1252109A1 (en) 2019-05-17
JP2022081597A (ja) 2022-05-31
EP4026829A1 (en) 2022-07-13
HUE057571T2 (hu) 2022-05-28
JP6816195B2 (ja) 2021-01-20
NZ618570A (en) 2015-07-31
AU2020204528A1 (en) 2020-07-30
CA3135440A1 (en) 2012-12-13
CY1122639T1 (el) 2021-03-12
ES2559850T3 (es) 2016-02-16
KR20190031593A (ko) 2019-03-26
CN103717575A (zh) 2014-04-09
JP2014522409A (ja) 2014-09-04
PL2718265T3 (pl) 2016-04-29
EP3290404B1 (en) 2019-12-11
PT3000808T (pt) 2017-11-23
HUE048044T2 (hu) 2020-05-28
JP7039682B2 (ja) 2022-03-22
AU2020204528B2 (en) 2022-07-14
SMT201700534T1 (it) 2018-01-11
US20120309977A1 (en) 2012-12-06
MX347709B (es) 2017-05-10
LT3290404T (lt) 2020-02-25

Similar Documents

Publication Publication Date Title
KR102000485B1 (ko) [(3-히드록시피리딘-2-카보닐)아미노]알칸산, 에스테르 및 아미드의 제조공정
HK40078298A (en) Process for preparing n-[[5-(3-chlorophenyl)-3-hydroxy-2-pyridinyl]carbonyl]-glycine from 5-(3-chlorophenyl)-3-hydroxy-2-pyridine carboxylic acid
HK40033676A (en) Process for preparing [(5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)-amino]acetic acid from 5-((3-chlorophenyl)-3-chloro-pyridin-2-yl)-nitrile, and process for preparing 5-((halophenyl)-3-halo-pyridin-2-yl)-nitrile derivatives
HK40033676B (en) Process for preparing [(5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)-amino]acetic acid from 5-((3-chlorophenyl)-3-chloro-pyridin-2-yl)-nitrile, and process for preparing 5-((halophenyl)-3-halo-pyridin-2-yl)-nitrile derivatives
HK1252109B (en) 5-((halophenyl)-3-halo-pyridin-2-yl)-nitrile derivatives as intermediates in the preparation of [(5-(halophenyl)-3-hydroxypyridine-2-carbonyl)-amino]alkanoic acid derivatives
HK1216173B (en) 5-((halophenyl)-3-hydroxy-pyridin-2-yl)-carboxylic acid derivatives as intermediates for the preparation of carbonylamino alkanoic acids, esters and amides thereof
HK1196616B (en) Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140106

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170411

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180628

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190116

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180628

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190315

PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190116

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20180921

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20190411

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20190315

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190116

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20180921

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190710

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190710

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20220622

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20230628

Start annual number: 5

End annual number: 5